LOTTE BIOLOGICS

LOTTE BIOLOGICS is excited to announce our participation in DCAT Week 2025, happening from March 17-20 in New York City! Join us at the prestigious Lotte New York Palace Hotel, Suite #4617, for an exclusive meeting to discuss our cutting-edge solutions in biologics, ADC production, and CDMO services. DCAT Week 2025 represents the premier event for the global bio/pharmaceutical manufacturing value chain, and we are thrilled to be part of this influential gathering. If you're attending, don't miss the chance to connect with us at Suite #4617. Please follow the link to our inquiries page to schedule a meeting with us! https://lnkd.in/gKxmCvgS We look forward to fostering valuable collaborations and driving innovation in the biotech industry. See you in New York! #DCAT2025 #LOTTEBIOLOGICS #CDMO #ADC #OneStopService

Following his appointment in December, James Park, CEO of LOTTE BIOLOGICS, recently made his inaugural trip to visit the Syracuse Bio Campus in New York, and to oversee the development of our cutting-edge Antibody-Drug Conjugate (ADC) production facility. Mr. Park expressed his gratitude to the dedicated team members working tirelessly to bring this project to fruition and was enthusiastic about the facility becoming operational by the first half of 2025 to support clinical and commercial ADC drug production. LOTTE BIOLOGICS continues to lead innovation in the biotech industry, combining exceptional expertise in monoclonal antibody drug substance (mAb DS) production with advanced ADC conjugation capabilities tailored to our clients' needs. With a one-stop ADC service at a single site, we aim to be the central hub of integrated ADC solutions, fostering growth in partnership with our clients. Explore LOTTE BIOLOGICS' ADC services and discover how we are driving excellence in biotechnology. https://lnkd.in/gJGEpXmz #LOTTEBIOLOGICS #Syracuse #ADC #Biotech #CDMO #drugdevelopment #manufacturing

We would like to extend our gratitude to everyone who came and showed interest in LOTTE BIOLOGICS at the 2025 JP Morgan Healthcare Conference. Your support and enthusiasm inspire us to continue driving innovation and excellence in the global CDMO industry. This year, we were thrilled to introduce our next-generation ADC platform, SoluFlex Link, and share the progress of our cutting-edge Songdo Bio Campus. These milestones represent our commitment to delivering advanced solutions and building strong partnerships that foster mutual growth. Thank you for taking the time to connect with us, through insightful discussions, business meetings, or simply stopping by to learn more about our vision. We look forward to collaborating with many of you and shaping the future of biopharmaceutical manufacturing together. For those who would like to learn more about LOTTE BIOLOGICS' ADC technology, please click the link below: https://lnkd.in/gJGEpXmz #ThankYou #JPMorganHealthcareConference #LOTTEBIOLOGICS #CDMO #ADCplatform #Partnership

Today, LOTTE BIOLOGICS participated in the 2025 JP Morgan Healthcare Conference, marking a significant milestone for our new CEO, James Park. His inaugural presentation centered on the theme, "Advancing as a Global CDMO Leader." During his speech, Mr. Park unveiled our groundbreaking SoluFlex Link ADC platform, which offers enhanced efficiency and stability for next-generation ADC development. This innovation showcases our commitment to driving transformative solutions in ADC manufacturing. Additionally, we highlighted the ongoing progress of our state-of-the-art Songdo Bio Campus. With Plant 1 scheduled for commercial production in 2027, this facility is set to redefine large-scale manufacturing capabilities through advanced automation and optimized processes. For more details about the presentation and our plans, visit our website: https://lnkd.in/g6RSBMG3 At LOTTE BIOLOGICS, we remain dedicated to elevating quality, fostering innovation, and delivering exceptional service as a trusted partner in the global CDMO industry. #JPMorganHealthcareConference #LOTTEBIOLOGICS #GlobalCDMO #Innovation #ADCplatform #SoluFlexLink #Biomanufacturing

We are excited to announce our participation in the JP Morgan Healthcare Conference again this year. LOTTE BIOLOGICS will be holding meetings with various industry stakeholders at our meeting room, located in Room 2678 at The Westin St. Francis. On Thursday January 16th, James Park, CEO of LOTTE BIOLOGICS, will be presenting at 1:15 PM. During his presentation, he will share insights into LOTTE BIOLOGICS' strategic vision as well as future plans for the biopharma and CDMO industries. If you are interested in knowing more about LOTTE BIOLOGICS or would like to engage in discussions about bio pharmaceutical CDMO opportunities, please feel free to visit us in Room 2678! #JPMorganHealthcareConference #LOTTEBIOLOGICS #Biotech #Pharmaceuticals #CDMO #Healthcare

LOTTE BIOLOGICS is preparing to begin operations of our cGMP ADC production facility at the Syracuse Bio Campus in the U.S. by March 2025. This advanced facility is designed to support the production of both clinical and commercial ADC drugs. By combining the monoclonal antibody drug substance (mAb DS) expertise of the Syracuse Bio Campus with our dedication to quality, we aim to provide optimized ADC conjugation services tailored to meet our clients' specific needs. Click on the link below to learn more about how we're pioneering innovation in this vital area of biotechnology. https://lnkd.in/gJGEpXmz #LOTTEBIOLOGICS #Syracuse #ADC #Biotech #CDMO #drugdevelopment #manufacturing

As the year comes to a close, we want to take a moment to reflect on 2024-a year of growth, innovation, and meaningful connections. We are truly grateful for our incredible employees, valued partners, and supportive community who have made this year so special. Wishing you and your loved ones a joyful holiday season filled with peace, happiness, and warmth. Here's to a successful and inspiring 2025 together! Happy Holidays from all of us at LOTTE BIOLOGICS! #SeasonsGreetings #HappyHolidays #LOTTEBIOLOGICS #Gratitude

We are proud to announce that James Park, CEO of LOTTE BIOLOGICS, will be presenting at the 43rd J.P. Morgan Healthcare Conference on January 16th at 1:15 PM PST. During his presentation, he will share insights into our strategic vision and future plans for the biopharma and CDMO industries.    The J.P. Morgan Healthcare Conference is a significant platform where industry leaders gather to shape the future of healthcare and biotechnology. We are excited to be part of this dynamic discussion and to showcase how LOTTE BIOLOGICS is contributing to growth in the CDMO space.     We look forward to connecting with industry peers and fostering impactful collaborations. See you there!     #JPM2025 #LOTTEBIOLOGICS #Biotech #CDMO #Innovation #Healthcare 

LOTTE BIOLOGICS is pleased to announce that James Park will assume the role of our new CEO, effective December 11. Mr. Park has a proven track record in operational excellence, strategic leadership, and corporate growth. His expertise will position LOTTE BIOLOGICS to become a key player in the global CDMO market while strengthening connections between our teams in Korea and the United States. To welcome Mr. Park and mark the beginning of this exciting new chapter, we held an inauguration ceremony at the Songdo Bio Campus site on December 13. This event symbolizes our commitment to innovation and growth under his leadership. Under his guidance, we are confident that we will achieve significant transformation, accelerate our global expansion, and foster a united, innovative culture. Join us in celebrating this exciting new chapter for LOTTE BIOLOGICS!

This Thanksgiving, we want to express our gratitude to our incredible team, valued partners, and supportive community. We’re thankful for the dedication, collaboration, and innovation that drive us forward each day. Wishing everyone a joyful and restful holiday filled with warmth, happiness, and good company. Happy Thanksgiving! #Thanksgiving #Gratitude #LOTTEBIOLOGICS #Thankful #Teamwork